Tanshinone II A sulfonate, but not tanshinone II A, acts as potent negative allosteric modulator of the human purinergic receptor P2X7

Journal of Pharmacology and Experimental Therapeutics

Volumn 350, Issue 3, 2014, Pages 531-542

  Kaiser, M ^a   Sobottka, H ^a   Fischer, W ^a   Schaefer, M ^a   Norenberg W ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; CYTOKINE; INTERLEUKIN 1BETA; PURINERGIC P2X4 RECEPTOR; PURINERGIC P2X7 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; PURINERGIC RECEPTOR STIMULATING AGENT; TANSHINONE IIA; TANSHINONE IIA SULFONATE; UNCLASSIFIED DRUG;

ALLOSTERISM; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CYTOKINE RELEASE; ELECTROPHYSIOLOGY; EMBRYO; FLUOROMETRY; HUMAN; HUMAN CELL; IC 50; INTRACELLULAR TRANSPORT; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RAT;

ANIMALS; CELL SURVIVAL; DITERPENES, ABIETANE; HEK293 CELLS; HUMANS; MICE; PHENANTHRENES; PURINERGIC P2X RECEPTOR ANTAGONISTS; RATS; RECEPTORS, PURINERGIC P2X7;

EID: 84905036073     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.214569     Document Type: Article

References (57)

1. Baroja-Mazo A and Pelegrín P (2012) Modulating P2X7 receptor signaling during rheumatoid arthritis: new therapeutic approaches for bisphosphonates. J Osteoporos 2012:408242.
2. Bernaert N, De Paepe D, Bouten C, De Clercq H, Stewart D, Van Bockstaele E, De Loose M, and Van Droogenbroeck B (2012) Antioxidant capacity, total phenolic and ascorbate content as a function of the genetic diversity of leek (Allium ampeloprasum var. porrum). Food Chem 134:669-677.
3. Birnbaumer L (2007) Expansion of signal transduction by G proteins: the second 15 years or so: from 3 to 16 a subunits plus betagamma dimers. Biochim Biophys Acta 1768:772-793.
4. 7) receptor antagonists for chronic inflammation and pain. Purinergic Signal 5:63-73.
5. Chu K, Yin B, Wang J, Peng G, Liang H, Xu Z, Du Y, Fang M, Xia Q, and Luo B (2012) Inhibition of P2X7 receptor ameliorates transient global cerebral ischemia/reperfusion injury via modulating inflammatory responses in the rat hippocampus. J Neuroinflammation 9:69.
6. Collingridge GL, Olsen RW, Peters J, and Spedding M (2009) A nomenclature for ligand-gated ion channels. Neuropharmacology 56:2-5.
7. Dong K, Xu W, Yang J, Qiao H, and Wu L (2009) Neuroprotective effects of tanshinone IIA on permanent focal cerebral ischemia in mice. Phytother Res 23:608-613.
8. Donnelly-Roberts DL, Namovic MT, Han P, and Jarvis MF (2009) Mammalian P2X7 receptor pharmacology: comparison of recombinant mouse, rat and human P2X7 receptors. Br J Pharmacol 157:1203-1214.
9. Duplantier AJ, Dombroski MA, Subramanyam C, Beaulieu AM, Chang SP, Gabel CA, Jordan C, Kalgutkar AS, Kraus KG, and Labasi JM, et al (2011) Optimization of the physicochemical and pharmacokinetic attributes in a 6-azauracil series of P2X7 receptor antagonists leading to the discovery of the clinical candidate CE-224,535. Bioorg Med Chem Lett 21:3708-3711.
10. Ferrari D, Chiozzi P, Falzoni S, Hanau S, and Di Virgilio F (1997) Purinergic modulation of interleukin-1 b release from microglial cells stimulated with bacterial endotoxin. J Exp Med 185:579-582.
11. Garcia-Guzman M, Soto F, Gomez-Hernandez JM, Lund PE, and Stühmer W (1997) Characterization of recombinant human P2X4 receptor reveals pharmacological differences to the rat homologue. Mol Pharmacol 51:109-118.
12. Gendaszewska-Darmach E and Kucharska M (2011) Nucleotide receptors as targets in the pharmacological enhancement of dermal wound healing. Purinergic Signal 7:193-206.
13. Gu BJ and Wiley JS (2006) Rapid ATP-induced release of matrix metalloproteinase 9 is mediated by the P2X7 receptor. Blood 107:4946-4953.
14. 7) nucleotide receptor function in human monocytes by extracellular ions and receptor density. Am J Physiol Cell Physiol 280:C943-C953.
15. Hatfield MJ, Tsurkan LG, Hyatt JL, Edwards CC, Lemoff A, Jeffries C, Yan B, and Potter PM (2013) Modulation of esterified drug metabolism by tanshinones from Salvia miltiorrhiza ("Danshen"). J Nat Prod 76:36-44.
16. Hempel C, Nörenberg W, Sobottka H, Urban N, Nicke A, Fischer W, and Schaefer M (2013) The phenothiazine-class antipsychotic drugs prochlorperazine and trifluoperazine are potent allosteric modulators of the human P2X7 receptor. Neuropharmacology 75:365-379.
17. Hille B (1992) Ionic Channels of Excitable Membranes, Sinauer Associates, Sunderland, MA.
18. Honore P, Donnelly-Roberts D, Namovic MT, Hsieh G, Zhu CZ, Mikusa JP, Hernandez G, Zhong C, Gauvin DM, and Chandran P, et al (2006) A-740003 [N-(1-[(cyanoimino) (5-quinolinylamino) methyl]amino-2,2-dimethylpropyl)-2-(3,4- dimethoxyphenyl) acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat. J Pharmacol Exp Ther 319:1376-1385.
19. Itoh T, Matsuda H, Tanioka M, Kuwabara K, Itohara S, and Suzuki R (2002) The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis. J Immunol 169:2643-2647.
20. Jiang LH, Baldwin JM, Roger S, and Baldwin SA (2013) Insights into the molecular mechanisms underlying mammalian P2X7 receptor functions and contributions in diseases, revealed by structural modeling and single nucleotide polymorphisms. Front Pharmacol 4:55.
21. Jutabha P, Kanai Y, Hosoyamada M, Chairoungdua A, Kim DK, Iribe Y, Babu E, Kim JY, Anzai N, and Chatsudthipong V, et al (2003) Identification of a novel voltage-driven organic anion transporter present at apical membrane of renal proximal tubule. J Biol Chem 278:27930-27938.
22. Khakh BS and North RA (2012) Neuromodulation by extracellular ATP and P2X receptors in the CNS. Neuron 76:51-69.
23. King BF (2007) Novel P2X7 receptor antagonists ease the pain. Br J Pharmacol 151: 565-567.
24. Kubick C, Schmalzing G, and Markwardt F (2011) The effect of anions on the human P2X7 receptor. Biochim Biophys Acta 1808:2913-2922.
25. Lazarowski ER, Watt WC, Stutts MJ, Boucher RC, and Harden TK (1995) Pharmacological selectivity of the cloned human P2U-purinoceptor: potent activation by diadenosine tetraphosphate. Br J Pharmacol 116:1619-1627.
26. 2+-controlled competitive diacylglycerol binding of protein kinase C isoenzymes in living cells. J Cell Biol 159:291-302.
27. Liu J, Morton J, Miedzyblocki M, Lee TF, Bigam DL, Fok TF, Chen C, Lee SK, Davidge ST, and Cheung PY (2009) Sodium tanshinone IIA sulfonate increased intestinal hemodynamics without systemic circulatory changes in healthy newborn piglets. Am J Physiol Heart Circ Physiol 297:H1217-H1224.
28. Liu X, Wang Y, Ma C, Zhang L, Wu W, Guan S, Yang M, Wang J, Jiang B, and Guo DA (2011) Proteomic assessment of tanshinone IIA sodium sulfonate on doxorubicin induced nephropathy. Am J Chin Med 39:395-409.
29. 7) receptor. Br J Pharmacol 153:737-750.
30. 7) receptor antagonists. Br J Pharmacol 156: 1312-1325.
31. Moreau A, Le Vee M, Jouan E, Parmentier Y, and Fardel O (2011) Drug transporter expression in human macrophages. Fundam Clin Pharmacol 25:743-752.
32. Nelson DW, Gregg RJ, Kort ME, Perez-Medrano A, Voight EA, Wang Y, Grayson G, Namovic MT, Donnelly-Roberts DL, and Niforatos W, et al (2006) Structure-activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists. J Med Chem 49:3659-3666.
33. Nörenberg W, Hempel C, Urban N, Sobottka H, Illes P, and Schaefer M (2011) Clemastine potentiates the human P2X7 receptor by sensitizing it to lower ATP concentrations. J Biol Chem 286:11067-11081.
34. Nörenberg W, Sobottka H, Hempel C, Plötz T, Fischer W, Schmalzing G, and Schaefer M (2012) Positive allosteric modulation by ivermectin of human but not murine P2X7 receptors. Br J Pharmacol 167:48-66.
35. North RA and Jarvis MF (2013) P2X receptors as drug targets. Mol Pharmacol 83: 759-769.
36. Perregaux D, Barberia J, Lanzetti AJ, Geoghegan KF, Carty TJ, and Gabel CA (1992) IL-1 beta maturation: evidence that mature cytokine formation can be induced specifically by nigericin. J Immunol 149:1294-1303.
37. Perregaux D and Gabel CA (1994) Interleukin-1 beta maturation and release in response to ATP and nigericin: evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity. J Biol Chem 269: 15195-15203.
38. Pham-The H, Gonzáles-Álvares I, Bermejo M, Garrigues T, Le-Thi-Thu H, and Cabrera-Pérez MÁ (2013) The use of rule-based and QSPR approaches in ADME profiling: a case study on Caco-2 permeability. Molecular Informatics 32:459-479.
39. Raja SG (2013) Sodium tanshinone IIA sulfonate for pulmonary arterial hypertension: emerging therapeutic option. J Thorac Dis 5:114-115.
40. Roth M, Obaidat A, and Hagenbuch B (2012) OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol 165:1260-1287.
41. Shang Q, Xu H, and Huang L (2012) Tanshinone IIA: a promising natural cardioprotective agent. Evid Based Complement Alternat Med 2012:716459.
42. Silberberg SD, Li M, and Swartz KJ (2007) Ivermectin interaction with transmembrane helices reveals widespread rearrangements during opening of P2X receptor channels. Neuron 54:263-274.
43. 7) receptors, AZ11645373. Br J Pharmacol 149:880-887.
44. Ca) activation in mouse cerebral arterial smooth muscle cells. Eur J Pharmacol 656:27-32.
45. Volonté C, Apolloni S, Skaper SD, and Burnstock G (2012) P2X7 receptors: channels, pores and more. CNS Neurol Disord Drug Targets 11:705-721.
46. von Kügelgen I and Harden TK (2011) Molecular pharmacology, physiology, and structure of the P2Y receptors. Adv Pharmacol 61:373-415.
47. Wang J, Lu W, Wang W, Zhang N, Wu H, Liu C, Chen X, Chen Y, Chen Y, and Jiang Q, et al. (2013) Promising therapeutic effects of sodium tanshinone IIA sulfonate towards pulmonary arterial hypertension in patients. J Thorac Dis 5:169-172.
48. Wang L, Zhang X, Liu L, Cui L, Yang R, Li M, and Du W (2010) Tanshinone II A down-regulates HMGB1, RAGE, TLR4, NF-kappaB expression, ameliorates BBB permeability and endothelial cell function, and protects rat brains against focal ischemia. Brain Res 1321:143-151.
49. Wu TW, Zeng LH, Fung KP, Wu J, Pang H, Grey AA, Weisel RD, and Wang JY (1993) Effect of sodium tanshinone IIA sulfonate in the rabbit myocardium and on human cardiomyocytes and vascular endothelial cells. Biochem Pharmacol 46:2327-2332.
50. Xu M, Dong MQ, Cao FL, Liu ML, Wang YX, Dong HY, Huang YF, Liu Y, Wang XB, and Zhang B, et al (2009) Tanshinone IIA reduces lethality and acute lung injury in LPS-treated mice by inhibition of PLA2 activity. Eur J Pharmacol 607:194-200.
51. Xu Y, Feng D, Wang Y, Lin S, and Xu L (2008) Sodium tanshinone IIA sulfonate protects mice from Con A-induced hepatitis via inhibiting NF-kappaB and IFN-γ/STAT1 pathways. J Clin Immunol 28:512-519.
52. Yan Z, Khadra A, Li S, Tomic M, Sherman A, and Stojilkovic SS (2010) Experimental characterization and mathematical modeling of P2X7 receptor channel gating. J Neurosci 30:14213-14224.
53. Yan Z, Khadra A, Sherman A, and Stojilkovic SS (2011) Calcium-dependent block of P2X7 receptor channel function is allosteric. J Gen Physiol 138:437-452.
54. Yang R, Liu A, Ma X, Li L, Su D, and Liu J (2008a) Sodium tanshinone IIA sulfonate protects cardiomyocytes against oxidative stress-mediated apoptosis through inhibiting JNK activation. J Cardiovasc Pharmacol 51:396-401.
55. +) channels by sodium tanshinoneII - A sulfonate (DS-201) in porcine coronary artery smooth muscle cells. Eur J Pharmacol 598:9-15.
56. Zhu H, Hao J, Chen H, Jiang S, Liu M, Sun H, Xu H, Zhang J, and Yang X (2013) Nanovesicles system for rapid-onset sublingual delivery containing sodium tanshinone IIA sulfonate: in vitro and in vivo evaluation. J Pharm Sci 102:2332-2340.
57. Zhu W, Lu Q, Chen HW, Feng J, Wan L, and Zhou DX (2012) Protective effect of sodium tanshinone IIA sulfonate on injury of small intestine in rats with sepsis and its mechanism. Chin J Integr Med 18:496-501.